Dermatologic Therapy最新文献

{"title":"Natural History and Prognostic Factors of Chronic Urticaria in Children Aged < 2 Years: A Single-Centered, Real-World, and Retrospective Study","authors":"Chun-Xiao Li,&nbsp;Hua-Guo Li,&nbsp;Bei-Bei Zhang,&nbsp;Yun Huang,&nbsp;Bei-Ming Wang,&nbsp;Yi-Hang Shen,&nbsp;Xiao-Xiao Wang,&nbsp;Wei-Qin Yang,&nbsp;Yan Gu,&nbsp;Yi-Feng Guo,&nbsp;Hui Zhang","doi":"10.1155/dth/1564070","DOIUrl":"https://doi.org/10.1155/dth/1564070","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> To date, a limited number of studies have reported on the natural course and prognostic factors of chronic urticaria (CU) among children aged &lt; 2 years.</p>\u0000 <p><b>Objective:</b> In this study, we delineated the characteristics and natural history of CU in children aged &lt; 2 years, with an additional aim of identifying prognostic factors closely associated with CU.</p>\u0000 <p><b>Methods:</b> This study included children aged &lt; 2 years who had CU between May 2019 and June 2023. The clinical data and laboratory results of these children were retrieved from their medical records or through telephone interviews.</p>\u0000 <p><b>Results:</b> The study population comprised 111 children with a median age of 16.30 (0.3–24) months at onset. Remission rates at 6, 12, and 36 months after the onset of CU were 36.08%, 51.55%, and 77.32%, respectively. After the sex and age at onset were adjusted, multivariate regression analysis revealed that allergic conjunctivitis was a risk factor for CU (OR_adjusted = 5.14 [95% CI, 1.03–28.52]).</p>\u0000 <p><b>Conclusion:</b> The course of CU in children aged &lt; 2 years is relatively short, with most children having a favorable outcome. Allergic conjunctivitis serves as a risk factor for CU in this age group.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1564070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation","authors":"Ji Yeon Hong,&nbsp;Kui Young Park","doi":"10.1155/dth/8855222","DOIUrl":"https://doi.org/10.1155/dth/8855222","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Neck aging presents challenges in achieving satisfactory cosmetic outcomes, particularly horizontal wrinkles. Minimally invasive technologies like microneedle radiofrequency (RF) devices offer promise for neck rejuvenation.</p>\u0000 <p><b>Aim:</b> This study evaluates the efficacy and safety of the novel microblade RF device for nonsurgical neck rejuvenation.</p>\u0000 <p><b>Methods:</b> Twelve healthy Korean volunteers received two microblade RF treatment sessions spaced 4 weeks apart. Skin biophysical properties were measured at baseline, Week 4, and Week 12. Assessments included Horizontal Neck Wrinkle Severity (HNWS) scores, Global Aesthetic Improvement Scale (GAIS) scores, and safety outcomes.</p>\u0000 <p><b>Results:</b> Significant reductions in HNWS scores were observed over time (<i>p</i> &lt; 0.001), alongside improved GAIS scores. Skin hydration increased, transepidermal water loss decreased, and skin elasticity improved at weeks 4 and 12. Treatment-related adverse effects were mild-to-moderate and transient, with no serious side effects reported.</p>\u0000 <p><b>Conclusion:</b> The microblade RF device demonstrates efficacy and safety for nonsurgical neck rejuvenation, with improvements in horizontal wrinkles and skin properties over time. These findings highlight its potential as a valuable tool in neck rejuvenation procedures.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8855222","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allopurinol-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Case Reports and Case Series","authors":"Shirin Borjikhani,&nbsp;Sholeh Ebrahimpour,&nbsp;Mehdi Mohammadi","doi":"10.1155/dth/6527730","DOIUrl":"https://doi.org/10.1155/dth/6527730","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Allopurinol is a known cause of mucocutaneous adverse drug reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis. The aim of this systematic review was to characterize the clinical presentation, identify risk factors, and evaluate the best treatment strategies for allopurinol-induced severe skin reactions.</p>\u0000 <p><b>Methods:</b> The PubMed, Embase, and Scopus databases were systematically searched to identify English case reports and case series of allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis. Animal studies, reviews, book chapters, randomized and nonrandomized human studies, observational studies, and conference abstracts were excluded. The Joanna Briggs Institute (JBI) critical appraisal checklists were used to assess the quality of the included studies.</p>\u0000 <p><b>Results:</b> Forty-seven case reports and 21 case series were included in the analysis, which reported 91 individual patient datasets. The reaction occurred after a median of 16 days (8.5 days in those with prior reactions to allopurinol). Rapid dose escalation was observed in half of the patients (21 of 43) for whom dose-increment schedules were reported. Mucosal involvement was observed in 72 (90.0%) patients. Corticosteroids, IVIG, cyclosporine, and plasma exchange were the most common treatment modalities. Twenty-one patients (23.6%) died, and 68 (76.4%) were discharged.</p>\u0000 <p><b>Conclusion:</b> Although gout is 2–3 times more common in men, the numbers of cases were similar in both sexes, likely due to higher reporting rates in women. Rapid dose escalation is a risk factor for the occurrence of severe skin reactions. Corticosteroids, IVIG, and plasma exchange appear to be reasonable treatment options.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6527730","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Influence of Different Treatment Intervals on the Efficacy of Hemoporfin-Mediated Photodynamic Therapy in Pediatric Patients With Port-Wine Stain on the Periphery of the Face","authors":"Jun Zhou,&nbsp;Jingchen Liang,&nbsp;Lu Cui,&nbsp;Ying Chen,&nbsp;Hongshan Liu,&nbsp;Zhao Wang,&nbsp;Yawen Wang,&nbsp;Shengzhi Mu,&nbsp;Fan Yang,&nbsp;Jing Liu,&nbsp;Weihui Zeng","doi":"10.1155/dth/6223746","DOIUrl":"https://doi.org/10.1155/dth/6223746","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) is considered an effective treatment for Port-wine stain (PWS). However, no studies have explored the effects of different treatment intervals on the efficacy of Hemoporfin-PDT. This study aimed to analyze the impact of different treatment intervals on the efficacy of Hemoporfin-PDT in pediatric facial PWS patients.</p>\u0000 <p><b>Methods:</b> A retrospective analysis was conducted based on the clinical data of 95 pediatric facial PWS patients who received Hemoporfin-PDT treatment from March 2018 to October 2023 in our center. The association between efficacy and sex, age, and treatment interval was analyzed.</p>\u0000 <p><b>Results:</b> After three sessions of Hemoporfin-PDT, 87.37% of patients achieved excellent or good efficacy, 11.58% had fair efficacy, and 1.05% had poor efficacy. The efficacy of patients with a 9-month treatment interval was significantly inferior to those with 3-month and 6-month intervals (OR: 6.99, 95% CI: 1.63–30.02, <i>p</i> = 0.009; OR: 10.92, 95% CI: 2.18–54.76, <i>p</i> = 0.004). However, there was no significant difference between patients with 3-month and 6-month intervals (<i>p</i> = 0.45). Sex and age were not found to be associated with the efficacy of Hemoporfin-PDT.</p>\u0000 <p><b>Conclusion:</b> In pediatric PWS patients with pink-type lesions located on the peripheral face, clinical efficacy is associated with the treatment interval. The efficacy of patients with a 9-month treatment interval is significantly inferior to those with 3-month and 6-month intervals. While the influence of age on the efficacy of Hemoporfin-PDT remains inconclusive, we still believe that early initiation of treatment is beneficial and necessary.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6223746","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Water Bathing on Atopic Dermatitis Are Determined by the Constituents in the Water","authors":"Dongyun Lei,&nbsp;Jiechen Zhang,&nbsp;Bijun Xia,&nbsp;Tingting Zhu,&nbsp;Lin Li,&nbsp;Canyi Gong,&nbsp;Litao Zhang,&nbsp;Mao-Qiang Man","doi":"10.1155/dth/3695790","DOIUrl":"https://doi.org/10.1155/dth/3695790","url":null,"abstract":"<div>\u0000 <p>Atopic dermatitis (AD) is a common skin disorder. Although a wide range of therapeutic regimens are available, they have some limitations, including high medical costs. However, evidence suggests that adjuvant regimens such as water bathing are inexpensive and effective approaches for the management of AD. Bathing with either tap water or seawater alone can improve AD symptoms and signs. Combination of water bathing with topic emollient or corticosteroids can synergically alleviate AD. The underlying mechanisms by which water bathing benefits AD include improvements in epidermal function, inhibition of mast cell and Langerhans cell function, reductions in serine protease expression and activity, inhibition of cytokine expression, and upregulation of expression levels of antioxidant enzymes, as well as antimicrobial peptides. In this review, we summarize the effects of water bathing on AD in both humans and murine models as well as the underlying mechanisms.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3695790","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Strategies and Decision-Making to Optimize Psoriasis Treatment: A French National Survey Based on Virtual Case Vignettes","authors":"Nathalie Quiles-Tsimaratos,&nbsp;Nicole Jouan,&nbsp;Annie Vermersch-Langlin,&nbsp;Anne-Bénédicte Duval-Modeste,&nbsp;Cristèle Nicolas,&nbsp;Caroline Lislaud,&nbsp;Baptiste Roux,&nbsp;Emmanuel Mahé","doi":"10.1155/dth/7294541","DOIUrl":"https://doi.org/10.1155/dth/7294541","url":null,"abstract":"<div>\u0000 <p>Despite current treatments for psoriasis, effective disease control remains challenging for physicians. Current recommendations provide information on when treatment should be optimized, but providing guidance on how to optimize treatments in real-word practice is complex. To examine the decision-making practices of dermatologists when optimizing the management of mild or moderate-to-severe psoriasis, we conducted a nationwide, virtual case vignette-based survey among French dermatologists. Participants reviewed four case vignettes. Data on management suggestions from the dermatologists were collected using questionnaires embedded in the case vignettes. Ninety dermatologists reviewed 356 virtual case vignettes. Of these, 99.4% contained a randomly generated profile describing a virtual psoriasis patient who had responded to current therapy but required treatment optimization, and 23.0% involved mild psoriasis treated with topical treatments, 77.0% involved moderate-to-severe psoriasis treated by conventional systemics or biologics, 59.9% involved psoriasis that had moderate or severe-to-very severe impact on HRQoL, 48.6% had joint involvement, and 58.7% had persistent skin lesions. For virtual patients with mild psoriasis involving topical treatments alone (<i>n</i> = 82), the dermatologists suggested switching or modifying the treatment in 81.7% of cases, most commonly by initiating conventional oral systemic therapy. For virtual cases with moderate-to severe psoriasis involving conventional oral systemic therapies (<i>N</i> = 90), the most common suggestion was to switch treatment (54.4% of cases), most notably to biologic therapy. Switching to a second-line or subsequent-line biologic was the most common suggestion for virtual cases already undergoing biologic therapy. Overall, modifying the existing treatment was suggested for 31.5% of the virtual cases, most notably by introducing new treatment combinations (biologics with conventional systemic and/or topical treatments). Impact on HRQoL, joint involvement, and persistent skin lesions were identified as factors influencing dermatologist decision-making (<i>p</i> &lt; 0.001). Our findings provide valuable insights into the current decision-making practices of French dermatologists when optimizing the management of mild or moderate-to-severe psoriasis.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7294541","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143809793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Autoimmune Skin Diseases Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis Using the FAERS Database","authors":"Zi-Yue Dong,&nbsp;Ming-Jie He,&nbsp;Yuan Hu","doi":"10.1155/dth/9922950","DOIUrl":"https://doi.org/10.1155/dth/9922950","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Immune checkpoint inhibitors (ICIs) revolutionize cancer therapy but frequently cause immune-related adverse events (irAEs), with autoimmune skin diseases (ASDs) being significant toxicities requiring careful management.</p>\u0000 <p><b>Objective:</b> This study explores the association between ICIs and 10 common ASDs using the FAERS database, aiming to identify risk profiles, time-to-onset patterns, and clinical implications.</p>\u0000 <p><b>Methods:</b> A retrospective pharmacovigilance analysis of FAERS data (2011Q1–2024Q4) was conducted, focusing on reports involving seven ICIs. Disproportionality algorithms (ROR, PRR, BCPNN, and MGPS) and statistical methods, including Kaplan–Meier and Weibull models, were employed to evaluate ASD risk and onset patterns.</p>\u0000 <p><b>Results:</b> Among 1670 cases, bullous pemphigoid (BP) showed the strongest association, particularly with PD-1/PD-L1 inhibitors, and other prominent ASDs, including vitiligo, psoriasiform dermatitis, lichen planus, and dermatomyositis. Scleroderma, Henoch–Schönlein purpura, pemphigus, alopecia areata, and systemic lupus erythematosus exhibited limited or inconsistent signals across different ICIs. The median time-to-onset was 143 days, with early onset linked to ipilimumab and atezolizumab. Reports predominantly involved males (62.8%) and patients ≥ 65 years old (51.7%), with the United States and Japan contributing most cases.</p>\u0000 <p><b>Conclusions:</b> BP, vitiligo, psoriasiform dermatitis, lichen planus, and dermatomyositis are key irAEs of ICIs, requiring vigilant monitoring and individualized management strategies. Limitations include biases in spontaneous reporting and underrepresentation of newer ICIs.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9922950","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143801518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electrochemotherapy for Multiple Nonmelanoma Skin Tumors in Immunosuppressed Patients: A Prospective Cohort Analysis","authors":"Petra Rózsa,&nbsp;Benjamin Tamás Papp,&nbsp;Edit Szederkényi,&nbsp;Gábor Vass,&nbsp;Csilla Hánis,&nbsp;Ildikó Csányi,&nbsp;Henriette Ócsai,&nbsp;Eszter Baltás,&nbsp;Judit Oláh,&nbsp;Lajos Kemény,&nbsp;Rolland Gyulai,&nbsp;Erika Kis","doi":"10.1155/dth/7037657","DOIUrl":"https://doi.org/10.1155/dth/7037657","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Immunosuppressed patients face a significantly higher risk of developing malignant skin tumors compared to the general population, often presenting with numerous, rapidly growing, and aggressive lesions. It can be particularly challenging to treat these tumors, especially in the head and neck region. Electrochemotherapy (ECT) emerges as a viable option for treating multiple tumors simultaneously. This study aims to compare the efficacy, toxicity, and impacts on the quality of life of ECT of nonmelanoma skin cancers (NMSCs) in immunosuppressed patients and nonimmunosuppressed patients.</p>\u0000 <p><b>Materials and Methods:</b> A total of 156 tumors (82 target lesions) in 14 immunosuppressed patients and 183 tumors (157 target lesions) in 30 nonimmunosuppressed patients were treated with ECT using intravenous bleomycin according to the European Standard Operating Procedures of ECT (ESOPE) guidelines. Patients were monitored for at least 6 months. A prospective cohort analysis was carried out to compare tumor response, side effects, and quality of life in the two groups.</p>\u0000 <p><b>Results:</b> 3 months after ECT, nonimmunosuppressed patients showed a significantly higher tumor response rate (<i>p</i> = 0.001). After 6 months, a statistically significant difference was not observed between the two groups regarding tumor response. After 3 and 6 months, there was no difference in toxicity, pain, and EQ-VAS values.</p>\u0000 <p><b>Conclusions:</b> Our results suggest that the effectiveness and safety of ECT for treating NMSCs in immunosuppressed patients seems to be comparable to the nonimmunosuppressed patients. The emphasis on prevention, adopting a multidisciplinary approach, and optimizing immunosuppression are crucial to improving the care and management of this patient cohort.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7037657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143770008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of 1064-nm Nanosecond Laser Modalities (Q-NDY and MDF Handpieces) for Treating Hand Skin Aging: A Prospective Randomized Controlled Trial","authors":"Jiying Dong,&nbsp;Shanshan Yao,&nbsp;Shen Wang,&nbsp;Min Yan,&nbsp;Nan Lu,&nbsp;Wenjuan Zhang,&nbsp;Min Yao","doi":"10.1155/dth/4994054","DOIUrl":"https://doi.org/10.1155/dth/4994054","url":null,"abstract":"<div>\u0000 <p><b>Background and Objectives:</b> Hand aging is complex, and while laser treatments effectively address pigmentation, their precise impact on skin thickness and wrinkles remains unclear. This study evaluates the effects of two 1064-nm nanosecond laser modalities (Q-switched Nd:YAG laser (Q-NDY) and multidepth fractional laser (MDF)) on hand skin rejuvenation and safety.</p>\u0000 <p><b>Materials and Methods:</b> A randomized controlled trial involving 20 patients with hand aging signs was conducted. Participants were randomized to the Q-NDY or MDF group, receiving three treatments at four-week intervals, followed by a three-month follow-up. Outcomes were evaluated by two independent plastic surgeons using an observer-reported scale. Skin physiology (thickness, melanin, and erythema indices) was measured, and patient satisfaction was assessed using the patient satisfaction scale (PSS).</p>\u0000 <p><b>Results:</b> Both modalities improved pigmentation and reduced wrinkles. The MDF group showed significantly greater improvement in fine wrinkles (<i>p</i> = 0.0086) and skin texture (<i>p</i> = 0.0209) and a significant increase in skin thickness (<i>p</i> &lt; 0.01), whereas the Q-NDY group did not. Melanin and erythema indices decreased significantly by week 20, with a greater reduction in erythema in the MDF group (<i>p</i> = 0.021). Overall satisfaction was 75% for Q-NDY and 90% for MDF.</p>\u0000 <p><b>Conclusion:</b> Both 1064-nm nanosecond laser modalities rejuvenate hand skin. The MDF mode showed superior outcomes in wrinkle reduction, skin texture, and thickness, offering a safe and effective treatment option for hand rejuvenation.</p>\u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: MR-31-23-013044</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4994054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study","authors":"Tiago Torres,&nbsp;Antonio Martorell,&nbsp;Paulo Leal Filipe,&nbsp;Caridad Soria,&nbsp;Fernando Mota,&nbsp;José Pardo,&nbsp;Miquel Ribera,&nbsp;Ricardo Ruiz-Villaverde","doi":"10.1155/dth/7529636","DOIUrl":"https://doi.org/10.1155/dth/7529636","url":null,"abstract":"<div>\u0000 <p><b>Background and Aim:</b> Quality of life (QoL) of psoriasis patients treated with calcipotriol/betamethasone dipropionate (Cal/BD) foam has not been thoroughly evaluated in real-world settings. This study evaluated the change in plaque psoriasis patients’ QoL after 4 weeks of first treatment with Cal/BD foam and after 6 months under daily practice conditions.</p>\u0000 <p><b>Methods:</b> A prospective, noninterventional study evaluated QoL, treatment adherence, satisfaction, and efficacy through the dermatology life quality index (DLQI), the Morisky-Green scale, the treatment satisfaction questionnaire for medication (TSQM-9), and the change in the body surface area (BSA) with plaque psoriasis, among others.</p>\u0000 <p><b>Results:</b> A total of 172 adult patients with plaque psoriasis were included. After 4 weeks of treatment, 53.5% of patients had a DLQI score ≤ 1. Mean absolute change in the DLQI score from baseline was −4.2 after 4 weeks of treatment and −4.0 after the 6-month follow-up (<i>p</i> &lt; 0.0001). Improvement in the BSA was statistically significant after the first treatment period and after the 6-month follow-up with a mean reduction of 2.4% and 2.6%, respectively (<i>p</i> &lt; 0.0001). Mean absolute change in global satisfaction between the end of the 4-week treatment period and the 6-month follow-up was −4.3 (<i>p</i> = 0.0049). In total, 41% of patients were compliant after the first treatment period, and 55.3% were moderately compliant. Higher patient treatment satisfaction was moderately correlated with lower DLQI scores after 4 weeks (<i>r</i> = −0.527; <i>p</i> &lt; 0.0001). Statistically significant differences between DLQI groups were found in the BSA: patients with DLQI ≤ 1 after 4 weeks of treatment had a lower BSA than patients with DLQI &gt; 1 (1.3 ± 1.8 vs. 2.8 ± 2.7, respectively; <i>p</i> &lt; 0.0001).</p>\u0000 <p><b>Conclusion:</b> After 4 weeks of treatment, daily use of Cal/BD foam in plaque psoriasis patients resulted in an improvement in QoL that was related to an improvement in both satisfaction and efficacy.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7529636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}